Navigation Links
Burnham researchers present at 100th AACR Meeting

LA JOLLA, Calif., April 17, 2009 -- Burnham Institute for Medical Research (Burnham) is pleased to announce that five of its postdoctoral fellows will present seven papers on their data at the American Association for Cancer Research (AACR) 100th Annual Meeting 2009. In addition, John C. Reed, M.D., Ph.D., Burnham President and CEO, Professor and Donald Bren Presidential Chair, will chair a panel on Apoptosis-based Strategies for Cancer Therapy, where he will also present his own research.

This year's meeting, being held in Denver from April 18 to 22, will highlight the best cancer science and medicine from institutions all over the world. In addition to Dr. Reed, Burnham researchers presenting at the AACR meeting include:

  • Lilach Agemy, Ph.D., who will present Nanoparticle-induced Vascular Blockade in Prostate Cancer.
  • Jason Garrison, Ph.D., who will discuss ARTS and Siah Collaborate in a Novel Pathway for XIAP Degradation
  • Shi Ranxin, Ph.D., who will present two papers: Cyclosporin A Sensitizes Cancer Cells to Death Receptor-Mediated Apoptosis and Chemical Biology Strategy Reveals Pathway-Selective Inhibitor of NFκB Activation Induced by Protein Kinase C and Antigen Receptors.
  • Changming Fang, Ph.D., who will also present two papers: Ileal Bile Acid Binding Protein Mediates the Chemopreventative Effect of Ursodeoxycholic Acid by Activating Nuclear Receptor FXRα in Colorectal Cancer and Genetic Deletion of FXRα Promotes Colon Tumorigenesis in ApcMin/+ Mice
  • Adam Richardson, Ph.D., will present The Role of Pentose Phosphate Pathway in the Warburg Effect.


Contact: Josh Baxt
Burnham Institute

Page: 1

Related biology news :

1. The Burnham Buzz, February 2009
2. Burnham researchers discover on switch for cell death signaling mechanism
3. The Burnham buzz
4. Burnham researchers turn cancer friend into cancer foe
5. Burnham researcher awarded $8 million grant
6. Yale researchers uncover secrets of salmonellas stealth attack
7. Singapore researchers first to transform carbon dioxide into methanol
8. Researchers identify specific lung cancer susceptibility gene
9. CSHL researchers explain process by which cells hide potentially dangerous DNA segments
10. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
11. Biomedical researchers invited to design experiments for the International Space Station
Post Your Comments:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: